- Home
- KBSX vs KPTI Comparison
KBSX vs KPTI Comparison
Compare KBSX & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KBSX
- KPTI
- Stock Information
- Founded
- KBSX N/A
- KPTI 2008
- Country
- KBSX Taiwan
- KPTI United States
- Employees
- KBSX N/A
- KPTI N/A
- Industry
- KBSX Recreational Games/Products/Toys
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- KBSX Consumer Discretionary
- KPTI Health Care
- Exchange
- KBSX Nasdaq
- KPTI Nasdaq
- Market Cap
- KBSX 104.0M
- KPTI 90.7M
- IPO Year
- KBSX N/A
- KPTI 2013
- Fundamental
- Price
- KBSX N/A
- KPTI $0.66
- Analyst Decision
- KBSX
- KPTI Strong Buy
- Analyst Count
- KBSX 0
- KPTI 4
- Target Price
- KBSX N/A
- KPTI $5.00
- AVG Volume (30 Days)
- KBSX N/A
- KPTI 1.0M
- Earning Date
- KBSX N/A
- KPTI 02-27-2025
- Dividend Yield
- KBSX N/A
- KPTI N/A
- EPS Growth
- KBSX N/A
- KPTI N/A
- EPS
- KBSX N/A
- KPTI N/A
- Revenue
- KBSX N/A
- KPTI $148,442,000.00
- Revenue This Year
- KBSX N/A
- KPTI $6.67
- Revenue Next Year
- KBSX N/A
- KPTI $8.58
- P/E Ratio
- KBSX N/A
- KPTI N/A
- Revenue Growth
- KBSX N/A
- KPTI 1.77
- 52 Week Low
- KBSX N/A
- KPTI $0.58
- 52 Week High
- KBSX N/A
- KPTI $1.95
- Technical
- Relative Strength Index (RSI)
- KBSX N/A
- KPTI 44.20
- Support Level
- KBSX N/A
- KPTI $0.61
- Resistance Level
- KBSX N/A
- KPTI $0.73
- Average True Range (ATR)
- KBSX 0.00
- KPTI 0.08
- MACD
- KBSX 0.00
- KPTI -0.00
- Stochastic Oscillator
- KBSX 0.00
- KPTI 26.13
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.